NCT03660241 - A Renal Impairment Study for PF-04965842 | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 5, 2018

Primary Completion Date

November 5, 2019

Study Completion Date

November 5, 2019

Conditions

Renal Impairment

Interventions

DRUG

PF-04965842

PF 04965842 is a janus kinase (JAK) 1 inhibitor that is currently being developed for the treatment of atopic dermatitis (AD).

Trial Locations (4)

Orlando Clinical Research Center, Orlando

University of Miami Division of Clinical Pharmacology, Miami

University of Miami, Sylvester Comprehensive Cancer Center, Miami

Brussels Clinical Research Unit, Brussels